1. The benefit of sentinel lymph node biopsy in elderly patients with melanoma: A retrospective analysis of SEER Medicare data (2010-2018).
- Author
-
Shen N, Ramanathan S, Horns JJ, Hyngstrom JR, Bowles TL, Grossman D, and Asare EA
- Subjects
- Humans, Male, Female, Retrospective Studies, Aged, United States epidemiology, Aged, 80 and over, Neoplasm Staging, Melanoma pathology, Melanoma mortality, Sentinel Lymph Node Biopsy statistics & numerical data, SEER Program, Medicare statistics & numerical data, Skin Neoplasms pathology, Skin Neoplasms mortality
- Abstract
Background: Sentinel lymph node status is critical for melanoma staging and treatment. However, the factors influencing SLNB and its oncologic benefits in elderly patients are unclear., Methods: We conducted a retrospective analysis of patients aged ≥65 with clinically node-negative melanoma and Breslow depth ≥1 mm, using Surveillance, Epidemiology, and End Results Medicare database (2010-2018). Multivariable logistic regression assessed SLNB likelihood by demographic and clinical factors, and Cox-proportional hazard models evaluated overall and melanoma-specific mortality (MSM) for SLNB recipients versus non-recipients., Results: Of 13,160 melanoma patients, 62.29 % underwent SLNB. SLNB was linked to reduced all-cause mortality (HR: 0.65 [95%CI 0.61-0.70]) and MSM (HR: 0.76 [95%CI 0.67-0.85]). Older age, non-White race, male sex, and unmarried status was associated with decreased SLNB likelihood, while cardiopulmonary, neurologic, and secondary cancer comorbidities were associated with increased SLNB likelihood., Conclusions: Though less frequently performed, SLNB is associated with lower mortality in elderly melanoma patients. Advanced age alone should not contraindicate SLNB., Competing Interests: Declaration of competing interest The authors declare no conflicts of interest regarding the publication of this manuscript., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF